NOBELPHARMA CO., LTD. FDA Approval NDA 213478

NDA 213478

NOBELPHARMA CO., LTD.

FDA Drug Application

Application #213478

Documents

Letter2022-03-23
Label2022-03-25
Review2022-05-19

Application Sponsors

NDA 213478NOBELPHARMA CO., LTD.

Marketing Status

Prescription001

Application Products

001GEL; TOPICAL0.2%0HYFTORSIROLIMUS

FDA Submissions

TYPE 3; Type 3 - New Dosage FormORIG1AP2022-03-22PRIORITY

Submissions Property Types

ORIG1Null30

CDER Filings

NOBELPHARMA CO., LTD.
cder:Array
(
    [0] => Array
        (
            [ApplNo] => 213478
            [companyName] => NOBELPHARMA CO., LTD.
            [docInserts] => ["",""]
            [products] => [{"drugName":"HYFTOR","activeIngredients":"SIROLIMUS","strength":"0.2%","dosageForm":"GEL; TOPICAL","marketingStatus":"Prescription","te":"None","rld":"No","rs":"No"}]
            [labels] => [{"actionDate":"03\/22\/2022","submission":"ORIG-1","supplementCategories":"Approval","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2022\\\/213478s000lbl.pdf\"}]","notes":""}]
            [originalApprovals] => [{"actionDate":"03\/22\/2022","submission":"ORIG-1","actionType":"Approval","submissionClassification":"Type 3 - New Dosage Form","reviewPriority":"PRIORITY; Orphan","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2022\\\/213478s000lbl.pdf\"},{\"name\":\"Letter (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/appletter\\\/2022\\\/213478Orig1s000ltr.pdf\"}]","notes":">"}]
            [supplements] => 
            [actionDate] => 2022-03-22
        )

)

© 2022 FDA.report
This site is not affiliated with or endorsed by the FDA.